Inthelia Therapeutics


Inthelia Therapeutics is an innovative spin out company that originated from the RCSI University of Medicine and Health Sciences, We are developing a biomarker-guided precision medicine to reduce barrier damage that manifests as Sepsis, COVID-19 and other acute host responses to bacterial, viral or fungal pathogen infection. Inthelia’s non-antimicrobial approach aims to save lives and improve health of patients where there are limited or no treatment options while also mitigating against the risk of antimicrobial resistance.